Evonik stock slips to EUR 21.14, down 0.84% premarket
Published on 11/16/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvonik outlook and earnings date
- Jefferies cut Evonik to Hold from Buy on November 11 and reduced its 2027 EBITDA forecast by 9 percent to below EUR 2 billion.
- Evonik's fourth-quarter results and 2027 guidance are scheduled for March 4, 2027.
- The brokerage sees weaker support from Middle East supply disruptions and continued pressure on the company's return-on-capital target.
Evonik stock traded at 21.14 euros on Lang & Schwarz at 07:57 CET on Monday, November 16, 0.84 percent below the Xetra close of 21.32 euros on Friday, November 13.
The specialty chemicals maker enters the session after a more cautious earnings assessment from Jefferies. The brokerage moved its rating to Hold from Buy on November 11 and cut its 2027 EBITDA forecast by 9 percent to below EUR 2 billion, according to Yahoo Finance.
Jefferies said the earnings boost from Middle East supply disruptions is fading. It also sees a challenge for Evonik's long-term return-on-capital ambition: the brokerage forecasts 8.9 percent in 2029, below the company's 11 percent target. The assessment highlights exposure to energy-intensive plants and a regional sales footprint spanning Europe, the Middle East and Africa.
For investors, the next scheduled corporate milestone is the fourth-quarter report and 2027 guidance on March 4, 2027. That update should provide the next formal test of the earnings assumptions behind the revised brokerage view.
Broader market direction can be followed in current market reports.
